These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34244953)
1. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer. Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
3. [Construction and evaluation of a nomogram for predicting the prognosis of patients with colorectal cancer with peritoneal carcinomatosis treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. An SL; Ji ZH; Li XB; Liu G; Zhang YB; Gao C; Zhang K; Zhang XJ; Yan GJ; Yan LJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):434-441. PubMed ID: 37217351 [No Abstract] [Full Text] [Related]
4. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis. Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related]
6. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes. Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754 [TBL] [Abstract][Full Text] [Related]
7. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis]. Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170 [No Abstract] [Full Text] [Related]
8. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455 [TBL] [Abstract][Full Text] [Related]
9. RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases. Bhullar D; O'Dwyer S; Wilson M; Saunders MP; Kochhar R; Barriuso J; Aziz O Ann Surg Oncol; 2023 Feb; 30(2):792-801. PubMed ID: 36400886 [TBL] [Abstract][Full Text] [Related]
10. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716 [TBL] [Abstract][Full Text] [Related]
11. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Tonello M; Baratti D; Sammartino P; Di Giorgio A; Robella M; Sassaroli C; Framarini M; Valle M; Macrì A; Graziosi L; Coccolini F; Lippolis PV; Gelmini R; Deraco M; Biacchi D; Santullo F; Vaira M; Di Lauro K; D'Acapito F; Carboni F; Giuffrè G; Donini A; Fugazzola P; Faviana P; Sorrentino L; Scapinello A; Del Bianco P; Sommariva A Ann Surg Oncol; 2022 Jun; 29(6):3405-3417. PubMed ID: 34783946 [TBL] [Abstract][Full Text] [Related]
12. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223 [TBL] [Abstract][Full Text] [Related]
13. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis. Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802 [TBL] [Abstract][Full Text] [Related]
14. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence. Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409 [TBL] [Abstract][Full Text] [Related]
15. Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry. Kelly ME; O'Sullivan NJ; Bolger JC; Polignano F; Youssef H; Renehan A; Malcomson L; Alves S; Cecil T; Mulsow J; Moran B; Mohamed F; Br J Cancer; 2023 Jan; 128(1):42-47. PubMed ID: 36347966 [TBL] [Abstract][Full Text] [Related]
16. Effect of RAS and BRAF mutations on peritoneal metastasis risk and cytoreductive surgery/hyperthermic intraperitoneal chemotherapy efficacy in colorectal cancer: A systematic review and meta-analysis. Gao Z; Qi X; Wang R; Wen Z; Qi H; Ju M; Liu X; Wang J; Zhou H; Zhu Z; Liu X; Li K Eur J Surg Oncol; 2024 Sep; 50(9):108474. PubMed ID: 38870874 [TBL] [Abstract][Full Text] [Related]
17. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches. Chang SC; Fingerhut A; Chen WT Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126 [TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study. Livin M; Leonard D; Bachmann R; Remue C; Barbois S; Cotte E; Van Den Eynde M; De Cuyper A; Sinapi I; Van Maanen A; Kartheuser A Acta Gastroenterol Belg; 2022; 85(4):573-579. PubMed ID: 36566366 [TBL] [Abstract][Full Text] [Related]
19. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455 [TBL] [Abstract][Full Text] [Related]
20. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis. Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]